Biopharma family succession: Bial CEO António Portela’s strategy
In the high-stakes world of pharmaceutical innovation, few stories are as compelling as those of...
How AI, AlphaFold and Digital Twins are Transforming Biosolutions
Artificial intelligence is no longer a buzzword in biotech, it’s becoming core infrastructure. From protein...
Camurus CEO Fredrik Tiberg on Long-Acting Opioid Treatment
Turning Generics Into Game-Changing Therapies: Fredrik Tiberg of Camurus Explains the Power of Long-Acting Medicines...
Personalized Cancer Vaccines and Oncolytic Viruses: The Next Generation of Cancer Immunotherapy
For decades, cancer vaccines have promised much and delivered little. Early “off-the-shelf” approaches struggled to...
From Breakthrough to Maturity: How Cell Therapy Is Evolving
Cell therapy has come a long way in just over a decade. What began as...
Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach
Few areas of healthcare have saved more lives, or generated more debate, than vaccines. For...
Abivax’s Record NASDAQ Stock Surge After Phase 3 Data
In biotech, Phase 3 data can change everything, or end everything. Few stories capture that...
Free Database of the Top 100 Public Biotechs in Europe
The FlotBio Map is live at map.flot.bio 🙌 Here’s a bit of background FlotBio Map...
Why AI in Biopharma Didn’t Live Up to the Hype
AI has reshaped entire industries, from software development to entertainment, yet its impact in healthcare...
Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession
Antibody-drug conjugates (ADCs) and radiopharmaceuticals have moved from the fringes of biotech buzzwords into the...
